GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities

Por Roth, Jonathan D, Erickson, Mary R, Chen, Steve, Parkes, David G
Publicado em 2012

FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver

Por Papazyan, Romeo, Liu, Xueqing, Liu, Jingwen, Dong, Bin, Plummer, Emily M., Lewis, Ronald D., Roth, Jonathan D., Young, Mark A.
Publicado no J Lipid Res (2018)

Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies

Por Roth, Jonathan D., Roland, Barbara L., Cole, Rebecca L., Trevaskis, James L., Weyer, Christian, Koda, Joy E., Anderson, Christen M., Parkes, David G., Baron, Alain D.
Publicado em 2008

INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis

Por Roth, Jonathan D, Feigh, Michael, Veidal, Sanne S, Fensholdt, Louise KD, Rigbolt, Kristoffer T, Hansen, Henrik H, Chen, Li C, Petitjean, Mathieu, Friley, Weslyn, Vrang, Niels, Jelsing, Jacob, Young, Mark
Publicado no World J Gastroenterol (2018)

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH

Por Roth, Jonathan D., Veidal, Sanne S., Fensholdt, Louise K. D., Rigbolt, Kristoffer T. G., Papazyan, Romeo, Nielsen, Jens Christian, Feigh, Michael, Vrang, Niels, Young, Mark, Jelsing, Jacob, Adorini, Luciano, Hansen, Henrik H.
Publicado no Sci Rep (2019)